🟢 Crispr Therapeutics is trading 4.7% up in pre-market on November 4, 2026, amid broader market gains

Crispr Therapeutics is trading at $52.34, up 4.70%, with broader market gains a possible contributor; no clear company-specific catalyst surfaced for November 4.

• The supplied price context shows a $49.99 close on November 3.
• The November 2 earnings update reported $99 million in CASGEVY revenue, up 30% quarter-over-quarter, and a $111.4 million net loss. These results are recent context, not a confirmed explanation for the pre-market rise.